Effectiveness and Safety of Dabigatran and Warfarin in Real‐World US Patients With Non‐Valvular Atrial Fibrillation: A Retrospective Cohort Study
Year: 2015
Type: article
Study design: Observational Study
Abstract: BACKGROUND: The recent availability of dabigatran, a novel oral anticoagulant, provided a new treatment option for stroke prevention in atrial fibrillation beyond warfarin, the main therapy for years. Little is known about their real-world comparative effectiveness and safety, even less among patient demographic and clinical subgroups. METHODS AND RESULTS: Using a cohort of non-valvular AF patients initiating anticoagulation from October 2010 to December 2012 drawn from a large US database of commercial and Medicare supplement claims, we applied propensity score weights to Cox proportional hazards regression to assess the comparative effectiveness and safety of dabigatran versus warfarin. Analyses were repeated among clinical and demographic subgroups using stratum-specific propensity scores as an exploratory analysis. Of the 64 935 patients initiating anticoagulation, 32.5% used dabigatran. Compared with warfarin, dabigatran was associated with a lower risk of ischemic stroke or systemic embolism (composite adjusted Hazard Ratio [aHR], 95% CI: 0.86, 95% CI: 0.79 to 0.93), hemorrhagic stroke (aHR: 0.51, 0.40 to 0.65), and acute myocardial infarction (aHR: 0.88, 95% CI: 0.77 to 0.99), and no relation was seen between dabigatran and the composite harm outcome (aHR: 0.94, 95% CI: 0.87 to 1.01). However, dabigatran was associated with a higher risk of gastrointestinal bleeding (aHR: 1.11, 95% CI: 1.02 to 1.22). Estimates of effectiveness and safety appeared to be mostly similar across subgroups. CONCLUSIONS: Dabigatran could be a safe and potentially more effective alternative to warfarin in patients with atrial fibrillation managed in routine practice settings.
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,810
Awards: Patterns of use, comparative effectiveness, and safety of rotavirus vaccines, National Health Literacy Mapping to Inform Healthcare Policy, Should the elderly have lower dose of ACE inhibitors for prevention after AMI?, G5682867191, A retrospective cohort study of the safety of testosterone therapy in older men, CONTINUITY OF MEDICATION MANAGEMENT IN MEDICAID, UNC Clinical and Translational Science Award, Propensity Scores and Preventive Drug Use in the Elderly, Research Training: Health Care Quality and Patient Outcomes
OpenAlex ID: W2159229357
